Form SC 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000902664-23-005657
Filing Date
2023-11-20
Accepted
2023-11-20 16:15:10
Documents
2

Document Format Files

Seq Description Document Type Size
1 CELLDEX THERAPEUTICS, INC. p23-2861sc13g.htm SC 13G 63224
2 JOINT FILING AGREEMENT p23-2861exhibit99.htm EX-99.1 6115
  Complete submission text file 0000902664-23-005657.txt   71028
Mailing Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827
Business Address 53 FRONTAGE ROAD SUITE 220 HAMPTON NJ 08827 908-200-7500
Celldex Therapeutics, Inc. (Subject) CIK: 0000744218 (see all company filings)

EIN.: 133191702 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G | Act: 34 | File No.: 005-37761 | Film No.: 231422917
SIC: 2835 In Vitro & In Vivo Diagnostic Substances

Mailing Address 72 CUMMINGS POINT ROAD STAMFORD CT 06902
Business Address 72 CUMMINGS POINT ROAD STAMFORD CT 06902 203-890-2000
Point72 Asset Management, L.P. (Filed by) CIK: 0001603466 (see all company filings)

EIN.: 465064661 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G